FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
Summary: The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel—a drug used to treat rheumatoid arthritis and other inflammatory conditions—allowing Amgen to extend its monopoly over the biologic …
Why it matters: This matters if it changes how teams think about model governance, safety work, monitoring, or regulatory exposure around deployed AI systems.
What to watch: Watch for follow-on technical guidance, deployment constraints, evaluation details, or signs that the announcement changes actual production practice rather than just policy language.